Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tifinorphine
- Development stage
- Unknown
- Lead developer
- Beijing Ziduhongye Technology Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tifinorphine is a small molecule oripavine derivative being developed by Beijing Ziduhongye Technology Development Co., Ltd. for the treatment of opioid dependence. Pharmacologically, it functions as a partial agonist at the mu-opioid receptor (MOR) and an antagonist at the kappa-opioid receptor (KOR), a profile similar to that of buprenorphine. This dual mechanism is intended to alleviate withdrawal symptoms and reduce cravings while maintaining a lower risk of abuse and respiratory depression compared to full opioid agonists. The drug has been evaluated in Phase II clinical trials in China as an oral hydrochloride tablet formulation for relapse prevention in detoxified patients who have completed methadone maintenance or other detoxification protocols.
- Other names
- tifinorphine hydrochloride
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on tifinorphine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tifinorphine.